Advances in the application of nuclear medicine imaging in the diagnosis and treatment of systematic light chain amyloidosis
10.3760/cma.j.cn321828-20201012-00369
- VernacularTitle:核医学显像在系统性轻链型淀粉样变诊疗中的应用进展
- Author:
Xuezhu WANG
1
;
Chao REN
;
Zhenghai HUANG
;
Kaini SHEN
;
Jian LI
;
Xiao LI
;
Yining WANG
;
Fang LI
;
Li HUO
Author Information
1. 中国医学科学院、北京协和医学院北京协和医院核医学科、核医学分子靶向诊疗北京市重点实验室，北京 100730
- Keywords:
Amyloidosis;
Immunoglobulin light-chains;
Positron-emission tomography;
Radionuclide imaging;
Trends
- From:
Chinese Journal of Nuclear Medicine and Molecular Imaging
2022;42(4):243-247
- CountryChina
- Language:Chinese
-
Abstract:
Systematic light chain (AL) amyloidosis is the most common forms of amyloidosis, which manifests as multiple organ system involvement, rapid progress, dire prognosis, difficult therapy and high mortality. Many patients may miss the optimal treatment as a result of not being diagnosed timely. Therefore, early diagnosis and assessment of involved extent of AL are clinical focuses. Related clinical studies have demonstrated that nuclear medicine imaging can be non-invasive in detecting amyloid deposits. It can not only early assess the extent and distribution of amyloid deposits in systemic AL amyloidosis, but also offer the indications for risk stratification, treatment response monitoring and prognosis assessment of the patients, especially for positron amyloidosis-specific tracers, which may have great prospects in the future. This review summarizes the application of nuclear medicine imaging in the systematic AL amyloidosis.
